NCT07027280Recruiting
Noninvasive Intratumor Heterogeneity Evaluation in HNSCC
Noninvasive Intratumor Heterogeneity Evaluation in HNSCC With Multi-omics Insights and Therapeutic Targets
Source: ClinicalTrials.gov · Last updated 18 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study focuses on tumor heterogeneity, a core challenge in the field of oncology, and innovatively utilizes patient imaging data to deeply mine and analyze intratumoral heterogeneity. By constructing an imaging analysis model for tumor heterogeneity and associating this model with clinical, pathological, transcriptomic, and metabolomic data of patients, a multi-omics decoding of tumor heterogeneity is achieved. The main questions it aims to address are: Can the ITH model stratify patients' treatment efficacy and prognosis assessment? Can pathological and multi-omics sequencing map the mechanisms behind the ITH model?
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 700 (estimated)
- First submitted
- 10 Jun 2025
- Start date
- 27 Feb 2025
- Primary completion date
- 15 Jun 2025
- Lead sponsor
- First Affiliated Hospital of Chongqing Medical University
- Diseases
- Head and neck cancer, Childhood cancers
- NCT number
- NCT07027280
What you commit to
- Study type: Observational
- Planned participants: 700
- From 27 Feb 2025 to the primary completion date, 15 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who received chemotherapy or radiotherapy before surgery. Poor image quality. Tumors too small to be easily identified. History of other concurrent malignant tumors.
Who the study is looking for
- Pathologically confirmed head and neck squamous cell carcinoma (HNSCC). Complete clinical, imaging, and pathological data. Available complete follow-up information.
Age in the registry: 15 years to 89 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Chongqing Medical University Coordinator of this site? Confirm its status | Chongqing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.